GHRP-2, also known as Pralmorelin, is a synthetic peptide drug. It acts as ghrelin/growth-hormone secretagogue receptor agonist, being the first drug of this class introduced clinically. It's used, in a single dose formulation, as a diagnostic agent for growth hormone deficiency (GHD). Administration of GHRP-2 increases the plasmatic concentration of growth hormone. It was clinically tested for tratment of GHD and pituitary dwarfism. GHRP-2 has performance enhancing potential and is prohibited for athletes in section S2: Peptide Hormones, Growth Factors, Related Substances, And Mimetics of WADA (World Antidoping Agency) Prohibited List. In this work we developed and validated a screening method for GHRP-2 and it's two metabolites from urine on LC-HRMS (liquid chromatography coupled with high resolution mass spectrometry)(Q Exactive Plus from Thermo Scientific) and LC-MS/MS triple quadrupole (liquid chromatography coupled with mass spectrometry) (ABSciex QTrap 5500). The validation parameters evaluated were limit of detection, matrix effects, identification criteria, specificity, carry-over and extraction recovery. the evaluated parameters are in accordance with WADA technical documents, both methods being applicable for doping control application.
Meldonium is an anti-ischemia drug developed in 1970 by Ivars Kalvins at the USSR Latvia Institute of organic synthesis. Meldonium is reportedly capable of providing clinical benefit for those suffering from heart conditions, such as low blood flow to the heart and angina, as well as neurodegenerative disorders and bronchopulmonary diseases. It appears that the medical utility of meldonium derives mostly from its ability to modulate cellular energy metabolism<sup>1</sup>. This may be due to the drug lowering the consumption of fatty acids, while increasing utilization of carbohydrates for the production of energy. In short, meldonium is advertised as an energy-efficiency catalyst. Since 1 January 2016, it has been on the World Anti-Doping Agency (WADA) list of substances banned from use by athletes. In this work a screening and a confirmation method for Meldonium from urine were developed and validated on LC-MS/MS triple quadrupole (liquid chromatography coupled with mass spectrometry ) (ABSciex QTrap 5500). The validation parameters evaluated were limit of detection, matrix effects, identification criteria, specificity, carry-over and extraction recovery. The evaluated parameters are in accordance with WADA technical documents, both methods being applicable for doping control application.
Polysaccharide-based plasma volume expanders (PVEs) such as hydroxyethyl starch (HES) is on Prohibited List of World Anti-Doping Agency (WADA) because it can prevent dehydration and reduce haematocrit values to mask erythropoietin abuse. The aim of this study is to establish time consuming and reliable methods for doping control screening and confirmation of HES in urine samples. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) with the same column: 5μm Zorbax SB-C18 was used for detection and confirmation without further sample preparation. The method was validated for the parameters: specificity and matrix effect, limit of detection (250μg/mL), identification capability, carryover, robustness. The results of the both method were found to be suitable for the detection and confirmation of hydroxyethylstarch.